GlassScriptPhysician profile
Javier Alcid Duron Tabora
NPI 1356861496
$11,296.61
in general payments reported to CMS, 2019-2025
44 companies · $3,275 in 2025
The $3,275 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.76 · 2022: $1,067 · 2023: $3,489 · 2024: $3,440 · 2025: $3,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,091.92 |
| Education | $111.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,080.28 | 2022-2025 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $1,044.78 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $810.04 | 2020-2025 | Repatha, Repatha, Evenity |
| Mannkind Corporation | $751.23 | 2023-2025 | Afrezza |
| Corcept Therapeutics | $747.38 | 2022-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $706.30 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $698.02 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.52 | 2022-2025 | Jardiance |
| Insulet Corporation | $554.45 | 2022-2025 | Omnipod, Omnipod |
| Medtronic, INC. | $465.57 | 2022-2025 | Minimed 780g, Minimed 770g, Guardian Sensor (3) |
| Radius Health, INC. | $390.97 | 2023-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $343.82 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $313.15 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $311.50 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $232.28 | 2022-2025 | Isturisa |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $229.26 | 2023 | Tepezza |
| Kyowa Kirin, INC. | $198.79 | 2023-2024 | Crysvita |
| Sequel Med Tech, LLC | $176.20 | 2025 | Twiist |
| Abbvie INC. | $158.91 | 2022-2025 | Ubrelvy |
| Dexcom, INC. | $138.83 | 2023-2025 | Dexcom G6 Transmitter |
| Chiesi USA, INC. | $128.20 | 2024-2025 | Mycapssa, Myalept |
| Alexion Pharmaceuticals, INC. | $106.91 | 2022-2024 | Strensiq |
| Beta Bionics, INC. | $102.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascensia Diabetes Care US INC. | $89.24 | 2023-2025 | |
| Esperion Therapeutics, INC. | $88.80 | 2023-2025 | Nexletol |
| Neurocrine Biosciences, INC. | $82.27 | 2024-2025 | |
| Pfizer INC. | $82.25 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $81.23 | 2022 | |
| Ascendis Pharma Endocrinology INC | $62.79 | 2025 | Yorvipath |
| Amphastar Pharmaceuticals, INC. | $57.72 | 2024 | |
| Amarin Pharma, INC. | $50.31 | 2023 | |
| Merck Sharp & Dohme LLC | $47.08 | 2022-2023 | Steglujan, Steglatro |
| Madrigal Pharmaceuticals | $43.74 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $42.93 | 2024-2025 | Imcivree |
| Abbott Laboratories | $36.69 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $32.01 | 2022-2023 | Livalo |
| Amneal Pharmaceuticals LLC | $30.37 | 2024 | Unithroid |
| Halozyme INC | $29.31 | 2023 | |
| Cequr Corporation | $24.29 | 2025 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $18.68 | 2024 | Tlando |
| Tolmar, INC. | $18.30 | 2025 | Jatenzo |
| Amryt Pharma Holdings LTD | $15.68 | 2023 | Mycapssa |
| Antares Pharma, INC. | $12.78 | 2023 | Xyosted, Tlando, Nocdurna |
| Ultragenyx Pharmaceutical INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Duron Tabora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.